BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 9253780)

  • 1. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.
    Glaspy J
    Semin Hematol; 1997 Jul; 34(3 Suppl 2):20-6. PubMed ID: 9253780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D; George MJ; Harrison LB
    Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
    Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion: an integrated analysis of the Canadian experience.
    Quirt I; Kovacs M; Couture F; Turner AR; Noble M; Burkes R; Dolan S; Plante RK; Lau CY; Chang J
    Oncologist; 2006 Jan; 11(1):73-82. PubMed ID: 16401716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J; Couture F; Young S; McWatters KL; Lau CY
    J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
    Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
    Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy.
    Granetto C; Ricci S; Martoni A; Pezzella G; Testore F; Mattioli R; Lampignano M; Tacconi F; Porrozzi S; Gasparini G; Mantovani G;
    Oncol Rep; 2003; 10(5):1289-96. PubMed ID: 12883695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients.
    Heras P; Argyriou AA; Papapetropoulos S; Karagiannis S; Argyriou K; Mitsibounas D
    Eur J Cancer Care (Engl); 2005 May; 14(2):108-12. PubMed ID: 15842457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaemia management with epoetin alfa in lung cancer patients in The Netherlands.
    Biesma B; van de Werf PR; Melissant CF; Brok RG
    Lung Cancer; 2007 Oct; 58(1):104-11. PubMed ID: 17601632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
    Chu E; Einhorn LH; Lefebvre P
    J Support Oncol; 2006 May; 4(5):243-50. PubMed ID: 16724648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
    Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
    J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
    Crawford J; Cella D; Cleeland CS; Cremieux PY; Demetri GD; Sarokhan BJ; Slavin MB; Glaspy JA
    Cancer; 2002 Aug; 95(4):888-95. PubMed ID: 12209734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O; Mancuso A; Di Molfetta M; Diana F; Beccaglia P; Cortesi E; De Marinis F
    Lung Cancer; 2004 Oct; 46(1):119-24. PubMed ID: 15364140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
    Lefebvre P; Vekeman F; Sarokhan B; Enny C; Provenzano R; Cremieux PY
    Curr Med Res Opin; 2006 Oct; 22(10):1929-37. PubMed ID: 17022852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
    Straus DJ; Testa MA; Sarokhan BJ; Czuczman MS; Tulpule A; Turner RR; Riggs SA
    Cancer; 2006 Oct; 107(8):1909-17. PubMed ID: 16977654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.